Molecular structure of Everolimus, CAS Number: 159351-69-6
Everolimus (CAS 159351-69-6)
See product citations (7)
Alternate Names:
40-O-(2-Hydroxyethyl)rapamycin; 42-O-(2-Hydroxy)ethyl Rapamycin; Afinitor
Application:
Everolimus is an immunosuppresive inhibitor of FRAP (mTOR)
CAS Number:
159351-69-6
Purity:
≥98%
Molecular Weight:
958.22
Molecular Formula:
C53H83NO14
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Everolimus is a macrolide derived from rapamycin (sc-3504) with immunosuppressant properties shown to inhibit cell proliferation induced by growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.
Everolimus (CAS 159351-69-6) References
- Everolimus. Novartis. | Dumont, FJ. 2001. Curr Opin Investig Drugs. 2: 1220-34. PMID: 11717808
- Early clinical experience with a novel rapamycin derivative. | Nashan, B. 2002. Ther Drug Monit. 24: 53-8. PMID: 11805723
- Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. | Patsenker, E., et al. 2011. J Hepatol. 55: 388-98. PMID: 21168455
- Everolimus - a new approach in the treatment of renal cell carcinoma. | Anandappa, G., et al. 2010. Cancer Manag Res. 2: 61-70. PMID: 21188097
- Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. | Yamanaka, K., et al. 2013. Cancer Med. 2: 862-71. PMID: 24403259
- Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. | Gnant, M., et al. 2013. Breast Care (Basel). 8: 293-9. PMID: 24415983
- [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option]. | Gilabert, M., et al. 2014. Bull Cancer. 101: 325-33. PMID: 24691195
- Everolimus. | Hasskarl, J. 2014. Recent Results Cancer Res. 201: 373-92. PMID: 24756805
- Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer. | Ng, VC., et al. 2015. J Oncol Pharm Pract. 21: 433-42. PMID: 24964967
- Durable polymer everolimus-eluting stents: history, current status and future prospects. | Rodríguez-Arias, JJ., et al. 2020. Expert Rev Med Devices. 17: 671-682. PMID: 32543934
- Everolimus ameliorates Helicobacter pylori infection-induced inflammation in gastric epithelial cells. | Liu, J., et al. 2022. Bioengineered. 13: 11361-11372. PMID: 35506423
- Everolimus reduces BK polyomavirus infection by suppressing its replication and spread of infection. | Sato, N., et al. 2022. Antiviral Res. 208: 105456. PMID: 36328070
- Inducible erythromycin resistance in bacteria. | Weisblum, B. 1984. Br Med Bull. 40: 47-53. PMID: 6442874
Inhibitor of:
β-defensin 8, 1700021C14Rik, 1700021F02Rik, 2900062L11Rik, 4922501L14Rik, 4930408F14Rik, 4932411N23Rik, 4E-BP1, 4E-BP3 (EIF4EBP3), 7530416G11Rik, ADAL, ANKS6, ARV1, Arxes2, Barhl1, BCAS4, BinCARD, BPAG1n3, BRCAA1, BTN3A1, BY080835, C14orf145, C1orf14_1700012A16Rik, C2, Cables2, caveolin-2, CCDC51, CD200R2, Cid, CMBL, CMTM7, collectrin, COTE1, CSAGE, CT47C1, CWH43, CXorf22, CXorf48, DCIR3, DENND3, DEPDC5, DEPDC6, DKFZp761E198, DNB5, DSCR 1, E2F-5, EF-CBP1, EHZF, Evx-1, F8A3, FAM198A, Fibrocystin L, FKBP12, FKBP15, FKF1, FLJ34931_BC027072, folliculin, FRBZ1, FRG2A, GAGE3, gankyrin, GGH, GITRL, Gm128, Gm3336, Gm4788, GRB10, Gros1, HACE1, hamartin, HCCA2, Hepatocellular Carcinoma Marker, HHCM, HIP14L, HuB, Ig κ chain, IgD Chain, IL-11Rα, IL-13Rα2, IL-2, IL-2Rα, IL-2Rβ, ING3, ING4, Int-6, IRGQ1, KIAA1609, KIR3DL3, KRAP, Lce1i, LNX4, LOC100041241, LOC100041448, LOC643669, LOC645851, LOC646457, LOC647238, LOC666187, LOC728337, LOC729556, LRBA, LRP16, Ly-49N, Mam1, MAML3, Max, MerTK, MFRP, MGRN1, MTDH, MTERF, mTOR, N4BP3, NBPF7, NF2, NHSL2, Niban, NICE-1, NICE4, NKIAMRE, NKR-P1F, NPRL2, Olfr583, Olfr593, Olfr614, Olr1065, Olr111, Olr1155, Olr125, Olr1264, Olr129, Olr130, Olr1320, Olr1321, Olr1330, Olr1397, Olr144, Olr1558, Olr1561, Olr1622, Olr164, Olr1641, Olr1657, Olr185, Olr214, Olr223, Olr232, Olr233, Olr348, Olr363, Olr375, Olr410, Olr484, Olr517, Olr649, Olr684, Olr696, Olr724, Olr736, Olr766, Olr775, Olr788, Olr80, Olr83, Olr836, Olr838, Olr920, Olr956, Olr962, Olr982, OOSP1, OTTMUSG00000010694, OTTMUSG00000016453, OTTMUSG00000019256, OVCA1, PATE-N, Per1, PHIP, PL6, podoplanin, Polycystin-1, PPIL2, Ppp2r3d, PRAP1, Progerin, Proliferation Marker, PRR11, PRR14, PTOV1, Rag A, Rag D, Raptor, Ras-GRF2, RASSF10, RASSF2, RBKS, REDD-1, REDD-2, Renal Cell Carcinoma, Rhox3, Ribosomal Protein S6, RIM-BP3B, RIMKLA, RN-tre, RNF115, rolled, RPRC1, RSRC2, SCFD1, scute, Separase, Set1, SLC38A9, smarp, SPATA17, ST7L, SUR-5, T cell leukemia homeobox (TLX), TATDN3, TBC1D7, TCP-c, TDF, TFE3, TINAGL1, TOB1, Tor1, Tor2, TORC1, Trav12d-1, Trav7d-2, Trav7d-3, Trav8d-1, TSSC1, TTP-αL, TTYH1, tuberin, UMPS, V1RH16, V1RH20, V1RH21, V1RH3, Vmn1r191, Vmn2r46, WFIKKN2, Xlr4, YPEL, Zinc-finger protein (ZNF), and ZNF703.Activator of:
4E-T, ARIH1, Atg13, EGFL6, eIF-4γ, eIF3K, eIF4E1B, ELOVL7, Erd2, FKBP6, FKBP7, FXR2, GPATCH3, HLF, HSP 56, IL-20Rα, ILKAP, LARP1, MLE, NPRL3, Pep12, Pex13p, Pex14p, Pex7p, PHKB, PJA2, RSL1D1, Sly1, SSX4, SSX4B, SSX5, SSX6, SSX7, SSX8, SSX9, Tlg2, TMEM127, TRB-2, Vam3, and WDFY2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Everolimus, 5 mg | sc-218452 | 5 mg | $128.00 | |||
Everolimus, 50 mg | sc-218452A | 50 mg | $638.00 |